JUBLPHARMA - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Fundamental Rating: 3.4

Let’s break down Jubilant Pharmova (JUBLPHARMA) — a diversified pharma and life sciences player with a mixed bag of metrics but long-term thematic relevance 🧬💊

📊 Core Financials Analysis

Return Metrics

ROE: 9.50%, ROCE: 9.54% — moderate; not highly efficient but stable.

EPS: ₹28.9 — decent, aligning well with mid-cap pharma space.

Earnings Trend

PAT dipped from ₹153 Cr. to ₹102 Cr. — a -3.83% QoQ decline may hint at margin pressures or one-offs.

Balance Sheet Strength

Debt-to-equity: 0.44 — reasonable for a capital-intensive industry.

Dividend Yield: 0.43% — low, but consistent with its reinvestment needs.

📉 Valuation Snapshot

Metric Value Insight

P/E Ratio 38.1 🟠 Premium vs industry average of 34.0 — not a bargain

P/B Ratio ~2.94 Implies the market is pricing future growth

PEG Ratio 3.75 ⚠️ High PEG — expensive relative to growth expectations

📌 Valuation View: Market seems optimistic, but current price may not reflect earnings headwinds — fundamentals are priced in with a premium tag.

🧠 Business Model & Competitive Edge

Operates across pharmaceuticals, contract research (CRDMO), and active ingredients, with global exposure.

Strong presence in the U.S. and EU generics market, and expanding CDMO footprint.

Faces cost challenges and regulatory sensitivity common to the sector.

DII Holding ↑2.47%, FII ↑0.17% — rising institutional confidence is a plus, especially domestic.

📍 Technical Perspective & Entry Zone

Current Price: ₹1,153

Floating above DMA-50 (₹1,138) and DMA-200 (₹1,021) — trending positively.

RSI: 44.5 — neutral; not oversold but not overheated either.

MACD: +9.31 — bullish crossover, could support momentum.

📌 Suggested Entry Range

Ideal zone: ₹1,100–₹1,140, especially on dips or post-earnings clarity.

Support sits near ₹1,020; upside resistance close to ₹1,280.

🕰️ Long-Term Holding Guidance

Best suited for a 3–5 year horizon with expectations of growth from global formulations and CRDMO tailwinds.

Watch margins, U.S. FDA updates, and raw material costs — key levers affecting performance.

Positioning in CDMO and specialty APIs could unlock value over time, but patience is required.

Want to compare this with peers like Divi’s Labs, Syngene, or Lupin to see how the pharma basket stacks up? Let’s dissect and diversify your strategy 🔍📘.

Edit in a page